智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月16日斥资260.99万港元回购20万股。 ...

格隆汇12月16日丨歌礼制药-B(01672.HK)公告，12月16日耗资261万港元回购20万股。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列日期開始時的結存(註1) ...

Group 1 - The company believes its current stock price is undervalued and has decided to increase the share buyback fund from a maximum of HKD 300 million to HKD 500 million as of December 15, 2025 [1] - The increase in buyback funds is attributed to significant achievements, including a 13-week Phase II study in the US showing a weight reduction of up to 7.7% for the oral small molecule GLP-1 agonist ASC30 in overweight or obese subjects, with better gastrointestinal tolerance [1] - The selective small molecule agonist ASC47, targeting thyroid receptor β (THRβ), showed a weight reduction improvement of up to 56.2% when combined with semaglutide compared to semaglutide alone in obese subjects [1] Group 2 - The company’s financial position is stable, and the board believes the current trading price does not reflect its intrinsic value [2] - The updated share buyback proposal is expected to enhance the value of the shares and increase shareholder returns, reflecting the company's confidence in its long-term business prospects and growth potential [2] - As of October 2, 2025, the company has utilized approximately HKD 54.28 million (excluding expenses) to repurchase 4.586 million ordinary shares under the buyback authorization [2]

格隆汇12月16日丨歌礼制药-B(01672.HK)发布公告，有关董事会拟根据公司股东于股东周年大会上授予 董事会购回公司股份的一般授权行使其权力，使用最多3亿港元的资金(拨付自公司内部财务资源)在合 适时间于公开市场上购回股份。 董事会认为公司现时股价被低估，并于2025年12月15日决议将股份购回资金由最多3亿港元增至最多5亿 港元("经更新建议股份购回")，此经考虑公司取得的重要里程碑的重大成就，包括但不限于：(1)歌礼口 服小分子GLP-1激动剂ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体 重下降高达7.7%，且胃肠道耐受性更佳；(2)脂肪靶向甲状腺受体β(THRβ)选择性小分子激动剂ASC47与 司美格鲁肽联用在肥胖受试者中较司美格鲁肽单药减重效果相对提升高达56.2%；(3)有望成为同类最佳 口服小分子白细胞介素-17(IL-17)抑制剂ASC50美国I期研究取得积极的顶线结果；及(4)同类首创脂肪酸 合成酶(FASN)抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获中国国家药品监督管理局受理。 于2025年12月15日，公司自2025年10月2日起根据购回 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 擴大建議根據購回授權進行股份購回的規模 本公司現時的財務狀況穩健。董事會認為股份現時的成交價未能反映其內在價 值。董事會相信，經更新建議股份購回可提升股份的價值，從而提高股東的回 報。此外，董事會相信，經更新建議股份購回反映本公司對自身的長遠業務前景 及本公司的增長潛力充滿信心，且最終將可惠及本公司，並符合本公司及股東整 體的最佳利益。 1 經更新建議股份購回將以本公司除本公司二零一八年全球發售所得款項淨額及於 二零二五年八月二十五日完成的根據股東於二零二五年五月二十二日舉行的本公 司股東週年大會上授出的一般授權配售現有股份及補足認購新股份所得款項淨額 外之內部財務資源撥付。本公司不會在對本公司營運資金狀況造成重大不利影響 的情況下進行購回。本公司進行經更新建議股份購回時，將 ...

Group 1: Market Movements - Baoji Pharmaceutical-B (02659) surged over 3.2% amid its debut on the Hong Kong Stock Exchange, closing up 138.82% on its first day, with a market capitalization exceeding HKD 20 billion [1] - New Energy (01799) and Xinyi Solar (00968) saw declines of 3.01% and 3.67% respectively, as the photovoltaic sector faced weakness, with rumors of a 30 billion yuan investment for capacity storage by major companies [1] - Xpeng Motors-W (09868) and Li Auto-W (02015) dropped 4.88% and 2.67% respectively, following data from the China Association of Automobile Manufacturers indicating a month-on-month increase in production and sales [1] Group 2: Company-Specific News - Bolek Vision Cloud-B (02592) experienced a significant drop of nearly 15%, having previously doubled in price over 10 trading days, as it announced a new drug trial application to the FDA [2] - Hu Shang Ayi (02589) rose nearly 6% as Nayuki Tea expanded into the U.S. market, enhancing the international presence of Chinese tea brands [2] - Gold stocks fell sharply, with Zijin Mining (02899) and Shandong Gold (01787) declining by 4.29% and 4.94% respectively, following a report on the Bloomberg Commodity Index's upcoming rebalancing [2] Group 3: Cryptocurrency and Technology - Cryptocurrency ETFs faced significant declines, with notable drops in Bitcoin and Ethereum-related funds, as Bitcoin fell 3.3% from its record high, reflecting market pressures amid weak liquidity [3] - Oracle (ORCL.US) continued its downward trend, dropping 2.66% due to delays in delivering AI data centers for OpenAI, attributed to labor and material shortages [6] - Nvidia (NVDA.US) saw a slight increase of 0.73% after announcing the release of its third-generation language model, aimed at writing and programming tasks [6]

据悉，ASC50为歌礼自主研发的口服小分子IL-17靶向抑制剂，IL-17在银屑病等多种自身免疫及炎症性 疾病中已获充分的生物学验证并具备成熟商业价值。ASC50是一种新化学实体(NCE)，拥有美国和全球 化合物专利保护，专利保护期至2043年(不含潜在的专利延期)。 本文源自：智通财经网 消息面上，12月15日，歌礼制药-B发布公告，ASC50在美国开展的一项随机、双盲、安慰剂对照的I期 临床试验(NCT07024602)取得积极顶线结果，该试验是在健康受试者中进行的单剂量递增(SAD)研究， 旨在评估ASC50的安全性、耐受性、药代动力学及外周循环的白细胞介素-17A(IL-17A)靶向结合特征。 46名健康受试者接受了10毫克、30毫克、100毫克、200毫克、400毫克或600毫克ASC50，或匹配的安慰 剂给药。该研究的目标包括评估安全性、耐受性、药代动力学和靶向结合效果。 智通财经获悉，歌礼制药-B(01672)回暖近3%，截至发稿，涨2.01%，报13.2港元，成交额3184.24万港 元。 ...

智通财经APP获悉，歌礼制药-B(01672)回暖近3%，截至发稿，涨2.01%，报13.2港元，成交额3184.24万 港元。 消息面上，12月15日，歌礼制药-B发布公告，ASC50在美国开展的一项随机、双盲、安慰剂对照的I期 临床试验(NCT07024602)取得积极顶线结果，该试验是在健康受试者中进行的单剂量递增(SAD)研究， 旨在评估ASC50的安全性、耐受性、药代动力学及外周循环的白细胞介素-17A(IL-17A)靶向结合特征。 46名健康受试者接受了10毫克、30毫克、100毫克、200毫克、400毫克或600毫克ASC50，或匹配的安慰 剂给药。该研究的目标包括评估安全性、耐受性、药代动力学和靶向结合效果。 据悉，ASC50为歌礼自主研发的口服小分子IL-17靶向抑制剂，IL-17在银屑病等多种自身免疫及炎症性 疾病中已获充分的生物学验证并具备成熟商业价值。ASC50是一种新化学实体(NCE)，拥有美国和全球 化合物专利保护，专利保护期至2043年(不含潜在的专利延期)。 ...

Company News - China Shenhua (01088.HK) reported coal sales of 389.5 million tons for the first 11 months, a decrease of 7.7% year-on-year. November sales were 37 million tons, down 3.6% year-on-year [1] - China Metallurgical Group (01618.HK) signed new contracts worth RMB 958.13 billion in the first 11 months, an 8.6% decrease year-on-year, with overseas contracts amounting to RMB 75 billion, a 0.4% increase year-on-year [1] - China Eastern Airlines (00670.HK) saw a 6.51% year-on-year increase in passenger capacity in November, with passenger turnover up 10.35% year-on-year and a seat load factor of 87.37%, up 3.04 percentage points year-on-year [1] - China Southern Airlines (01055.HK) reported an 8.68% year-on-year increase in passenger capacity in November, with passenger turnover up 10.42% year-on-year and a seat load factor of 86.29%, up 1.36 percentage points year-on-year [1] - New China Life Insurance (01336.HK) recorded cumulative original insurance premium income of RMB 188.85 billion for the first 11 months, a 16% year-on-year increase [1] - AOS Group (01161.HK) announced annual results for the year ending September 30, 2025, with revenue of approximately HKD 981 million, a decrease of 0.19% year-on-year, and a net profit of HKD 80.887 million, a 19% year-on-year increase [1] - Hopson Development Holdings (00754.HK) reported total contract sales of approximately RMB 14.27 billion for the first 11 months, an 8.91% decrease year-on-year [1] - Agile Group (01813.HK) had a pre-sale amount of RMB 511 million in November, a decrease of 21.4% year-on-year [1] - Galen Pharmaceuticals (01672.HK) is expected to become a best-in-class oral small molecule IL-17 inhibitor, with positive topline results from its Phase I study in the U.S. [1] - Bole Technology (02592.HK) submitted a new drug clinical trial application for CBT-199 to the U.S. FDA [1] - China Supply Chain Industry (03708.HK) signed a strategic cooperation framework agreement with Golden Energy regarding digital assets [1] - Times China Holdings (01233.HK) had its liquidation petition withdrawn [1] - Botai Car Union (02889.HK) received a first project designation notice from a leading domestic new energy vehicle client [1] Buyback Activities - Haijia Medical (06078.HK) plans to repurchase 10% of its issued shares, with a repurchase amount of no less than RMB 300 million [1] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with repurchase prices ranging from HKD 602.5 to HKD 608 [1] - Xiaomi Group (01810.HK) repurchased 7.2 million shares for HKD 302 million, with repurchase prices ranging from HKD 41.78 to HKD 42 [1] Share Cancellation - Pacific Shipping (02343.HK) canceled 23.739 million repurchased shares [2]